Certara, Inc. Stock

Equities

CERT

US15687V1098

Software

Market Closed - Nasdaq 04:00:00 2024-05-01 pm EDT 5-day change 1st Jan Change
17.3 USD +1.11% Intraday chart for Certara, Inc. +5.17% -1.65%
Sales 2024 * 389M Sales 2025 * 430M Capitalization 2.77B
Net income 2024 * -9M Net income 2025 * 8M EV / Sales 2024 * 7.28 x
Net Debt 2024 * 60.83M Net cash position 2025 * 67.85M EV / Sales 2025 * 6.29 x
P/E ratio 2024 *
-
P/E ratio 2025 *
231 x
Employees 1,365
Yield 2024 *
-
Yield 2025 *
-
Free-Float 74.11%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.11%
1 week+5.17%
Current month+1.11%
1 month-3.89%
3 months+4.41%
6 months+40.08%
Current year-1.65%
More quotes
1 week
16.21
Extreme 16.21
17.92
1 month
15.78
Extreme 15.78
19.18
Current year
15.32
Extreme 15.32
19.87
1 year
11.81
Extreme 11.81
23.85
3 years
10.60
Extreme 10.6
45.48
5 years
10.60
Extreme 10.6
45.48
10 years
10.60
Extreme 10.6
45.48
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 19-05-31
Director of Finance/CFO 51 23-03-31
President 60 20-08-31
Members of the board TitleAgeSince
Director/Board Member 57 17-07-31
Director/Board Member 65 21-07-31
Chief Executive Officer 54 19-05-31
More insiders
Date Price Change Volume
24-05-01 17.3 +1.11% 600,625
24-04-30 17.11 +0.18% 463,977
24-04-29 17.08 +3.08% 406,771
24-04-26 16.57 +1.66% 321,644
24-04-25 16.3 -0.91% 351,230

Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT

More quotes
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development in the global biopharmaceutical industry. It is focused on producing medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its customers include life sciences companies of all sizes along with contract research organizations, academic institutions, and global regulators. Its software and service are used by approximately 2,400 biopharmaceutical companies and academic institutions across 66 countries, including 38 of the top 40 biopharmaceutical companies. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, Netherlands, Philippines, Poland, Portugal, Spain, Switzerland, Egypt, and the United Kingdom.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
17.3 USD
Average target price
19.74 USD
Spread / Average Target
+14.10%
Consensus